Little is known about outcomes of patients co-infected with human immunodeficiency virus (HIV) and tuberculosis (TB) who are treated in the private sector in India. O B J E C T I V E : To describe the treatment outcomes of daily anti-tuberculosis treatment (ATT) and their determinants among HIV-TB co-infected patients treated at a private clinic in Pune, India. D E S I G N : Data on adult HIV-TB co-infected patients treated with daily ATT were analysed using logistic regression and Cox model to assess risk factors for default and death. R E S U LT S : Of 769 cases, 78% were aged ,45 years, 71% were males, 64% had CD4 , 200 cells/mm 3 , 67% were antiretroviral treatment (ART) naïve at TB diagnosis, 53% had extra-pulmonary TB, and 12% had a past history of TB. ATT was successfully completed by 58.5%, 34.3% defaulted (i.e., discontinued ATT for .2 months) and 3.9% died during ATT. The risk of default was higher among males (aOR 1.67, 95%CI 1.17-2.39), ART-naïve patients (aOR 1.91, 95%CI 1.34-2.73) and those with a past history of TB (aOR 1.86, 95%CI 1.15-3.01). Survival probability at 365 days was 95% (95%CI 93-97). The risk of death was higher among patients with CD4 , 50 cells/mm 3 (aHR 4.63, 95%CI 1.47-14.65) than in those with CD4
had a past history of TB. ATT was successfully completed by 58.5%, 34.3% defaulted (i.e., discontinued ATT for .2 months) and 3.9% died during ATT. The risk of default was higher among males (aOR 1.67, 95%CI 1.17-2.39), ART-naïve patients (aOR 1.91, 95%CI 1.34-2.73) and those with a past history of TB (aOR 1.86, 95%CI 1.15-3.01). Survival probability at 365 days was 95% (95%CI 93-97). The risk of death was higher among patients with CD4 , 50 cells/mm 3 (aHR 4.63, 95%CI 1.47-14.65) than in those with CD4 . 200 cells/mm 3 . C O N C L U S I O N S : Low overall mortality was seen with daily ATT in HIV-TB co-infected patients. High default rates in private facilities warrant urgent attention. K E Y W O R D S : HIV-TB co-infection; daily ATT; treatment outcomes; private health care sector HUMAN IMMUNODEFICIENCY VIRUS (HIV) and tuberculosis (TB) are two major public health challenges being faced globally. 1 India, which has the third highest number of people living with HIV (PLHIV), also has a high TB burden. The World Health Organization (WHO) estimates that 2.1 million new TB cases occur annually in India, 2 120 000 of whom are co-infected with HIV. The synergistic association can worsen the prognosis for both diseases. [3] [4] [5] Overall, TB is estimated to cause about 25% of all deaths among PLHIV in India. Death rates as high as 15-18% are reported among HIV-infected TB cases notified under the Revised National Tuberculosis Control Programme (RNTCP). 6 A systematic review on anti-tuberculosis treatment (ATT) among PLHIV revealed that daily ATT during the intensive phase, compared to thrice-weekly regimens, was associated with lower failure and relapse rates. 7 A trend towards higher relapse rates was observed if rifampicin (RMP) containing regimens were used for 6 months vs. 8 months. 7 Compared to the standard RNTCP 6-month regimen, extended ATT for 9 months was observed to be superior in reducing recurrence. 8 Concurrent antiretroviral treatment (ART) and ATT was associated with lower mortality, relapse rates and acquired RMP resistance. [9] [10] [11] However, the effect of extended and/or daily ATT in the presence of ART remains unclear. 12 The 2010 WHO guidelines recommend daily ATT for PLHIV with active TB, at least during the intensive phase, and the initiation of ART as soon as possible. According to the guidelines, some experts promote prolonged ATT under certain conditions. 13 Because of the paucity of national evidence and operational ease, the RNTCP in India uses intermittent (thrice-weekly) supervised ATT of 6 months' duration, i.e., DOTS, among PLHIV. 14 It has recently started piloting daily DOTS in HIV-TB co-infected patients. RNTCP data show higher mortality among PLHIV than in patients not infected by HIV. It also reports higher death (25%) and default (10%) rates among PLHIV who were not on ART at the time of ATT compared to those already on ART (14% and 3%, respectively). 15 Data on the effectiveness of daily DOTS among PLHIV are not available from RNTCP settings.
In India, more than 50% of patients with active TB attend private facilities for TB care. 16, 17 Many private practitioners use unsupervised daily ATT. 18 Little is known about outcomes in patients treated with unsupervised daily ATT in the private sector, particularly among those with HIV-TB co-infection.
The present paper describes treatment outcomes with daily unsupervised ATT among HIV-TB coinfected patients accessing care through the private sector in India and factors influencing outcomes.
METHODS

Study setting
The study clinic, Prayas Amrita Clinic (Pune, India), run by a non-government organisation based in Pune, India, provides out-patient clinical care for PLHIV. Care is provided at low or no cost based on family income. All patients are informed about the availability of free ART and ATT in public sector facilities. HIV is diagnosed and managed according to national guidelines. 19 TB is diagnosed based on clinical examination and radiological or ultrasonography (USG) investigations. Further investigations, such as sputum, biopsy, fine-needle aspiration cytology and cerebrospinal fluid examination, are performed when required to establish a diagnosis. Daily ATT over an extended period of time is prescribed. The duration of ATT is individualised in a 3-month intensive phase, followed by a 9-month continuation phase; the decision to stop ATT is guided by symptom improvement and clearance of lesions on radiological and/or USG investigations. The data are maintained in paper and electronic format.
Study population and design
This is a retrospective analysis of HIV-infected adults enrolled at the study clinic from January 2004 to June 2013. De-identified electronic data were shared with the study investigators and the data were checked for inconsistencies. Queries were addressed by the clinician after referring to medical charts, and data in the electronic files were updated accordingly.
Inclusion criteria and definitions
All adult HIV-infected patients detected with active TB at any time during follow-up at the clinic were considered for analysis. The first TB episode after enrolment at the clinic for which daily ATT was initiated was assessed for short-term outcomes. The following outcome definitions were used: 1) treatment completed: ATT completed over the prescribed duration; 2) treatment default: the discontinuation of ATT for .2 months; the last date on which ATT was prescribed to the patient was considered the date of default; 13 3) treatment failure: worsening of lesions and/or bacteriological evidence that required change of ATT regimen at/after 2 months of ATT; 4) death: death while receiving ATT; and 5) transferred out: transfer to another clinic while on treatment, usually to government TB clinics, due to financial constraints. The ATT initiation date was used as a proxy for TB diagnosis.
Statistical analysis
A descriptive analysis was undertaken to understand the sociodemographic and clinical profiles of the patients, and short-term ATT outcomes. Logistic regression analysis with the stepwise selection procedure was used to analyse the association of study variables with default compared to completion of ATT. Patients who died during ATT were not considered for the analysis. Effects were entered into and removed from the model at a ¼ 0.15. Survival probability was estimated using KaplanMeier curves. The outcome event was death during ATT. The observation was censored at the time of obtaining any outcome other than death (i.e., completed, transferred out, failure or default). Among defaulters, follow-up and outcomes if ATT was re-initiated after default were not considered. The log-rank test was used to compare survival curves. The risk factors for death were assessed using Cox's semi-parametric regression model. Covariates with P , 0.1 were entered to build the multivariate model. The proportionality of hazard ratio (HR) was confirmed using analysis of Schoenfeld residuals.
Anticipating some amount of misclassification of outcomes among defaulters with uninformed censoring, sensitivity analysis was conducted by assuming three outcome scenarios for defaulting cases with uninformed censoring: 1) all (irrespective of CD4 count at TB diagnosis) had died; 2) all those with CD4 , 200 cells/mm 3 had died; and 3) all those with CD4 , 50 cells/ mm 3 had died.
Statistical analysis was performed using SAS, version 9.4 (Statistical Analysis System, Cary, NC, USA). As this was a secondary analysis of deidentified data, the requirement for ethical approval was waived.
RESULTS
Study population
Of the total 4226 adult PLHIV enrolled at the clinic during the study period, 1467 patients were ever diagnosed with TB (prior to or after enrolment); 769 cases had active TB during follow-up after enrolment and were treated with daily ATT. The treatment outcomes of the first active TB episode after enrolment at the clinic were assessed for outcomes (Appendix Figure The sociodemographic profile of the patients and clinical characteristics at the time of TB diagnosis are given in Table 1 . The majority of the patients were males (n ¼ 549, 71%). The median time to TB diagnosis after enrolment at the clinic was 2 days (IQR À1 to 75). At the time of TB diagnosis, the majority of patients were aged ,45 years (n ¼ 597, 78%), had CD4 , 200 cells/mm 3 (n ¼ 492, 64%) and were not on ART (n ¼ 517, 67%). Ninety-seven patients (12%) had a past history of TB. Past history of TB was more often reported among males than among females (15% vs. 8%, P ¼ 0.009) and among those on ART than among those not on ART (21% vs. 8%, P , 0.001). Overall, 33% (n ¼ 256) had pulmonary TB only (PTB), 53% (n ¼ 405) had extrapulmonary TB (EPTB) and 14% (n ¼ 108) had both PTB and EPTB. Although the proportion of PTB and PTB þ EPTB was higher among patients with CD4 count ,50 cells/mm 3 , the difference was not statistically significant (P ¼ 0.35).
Treatment outcomes
Of the 769 patients, 450 (58.5%) completed the prescribed duration of ATT, 264 (34.3%) defaulted and 30 (3.9%) died. There were 6 (0.8%) failures and 19 (2.5%) were transferred out (Appendix Table A Table 2) .
A total of 30 deaths occurred during ATT. The median time to death from ATT initiation was 112 days (IQR 61-208). Survival probability at 180 days and 365 days was respectively 96% (95%CI 95-97) and 95% (95%CI 93-97). Appendix Figure A. 2 shows the Kaplan-Meier survival curves overall and by CD4 count categories at the time of TB diagnosis. The log-rank test was statistically significant for age at TB diagnosis (P ¼ 0.02), CD4 count at TB diagnosis (P ¼ 0.006), ART status at TB diagnosis (P ¼ 0.02) and previous history of TB (P ¼ 0.01).
As shown in Among defaulters (n ¼ 264), 70% were permanently lost to follow-up (LTFU). There was no information about the survival rates among these patients, leading to uninformed censoring. We compared profiles of cases with uninformed censoring with those whose survival status after default was known. The proportion of uninformed censoring was higher among females, patients with PTB þ EPTB, those with CD4 count ,200 cells/mm 3 and a previous history of TB. However, the difference was not statistically significant. The sensitivity analysis of survival probability at 365 days, as described in the Methods, for assumed outcome scenarios 1, 2 and 3, was respectively 71% (95%CI 67-74), 75% (95%CI 72-78) and 88% (95%CI 85-90).
DISCUSSION
A large number of TB patients in India seek care in the private sector. 17 To the best of our knowledge, this is one of the first reports on treatment outcomes of HIV-TB co-infected patients seeking care in the private sector in India.
At the time of TB diagnosis, the majority of the patients had low CD4 counts and were not on ART. Almost half had only EPTB, highlighting the importance of using a screening tool that combines symptom assessment with USG of the abdomen and CD4 count in HIV-TB co-infection settings. 8 It is also important to routinely implement active TB screening at all private facilities providing care to PLHIV. 6 A higher default rate was seen in this study cohort than in the RNTCP (34% vs. 4.4-15%). 15, 20, 21 The majority of private clinics in India provide unsupervised ATT. A typical treatment-seeking pathway has been observed in TB patients in India: an initial consultation with pharmacist or informal health care provider, generally followed by one or more visits to private providers, 22 and finally, after much delay, TB diagnosis and treatment in the public sector. 17 This partly explains the high default rate seen in our study. Attrition during the pre-ART phase has also been a challenge for HIV programmes in the country. Many PLHIV detected in the early stage of HIV disease are LTFU and return to care only when symptomatic. 23 In the present study, ART-naïve patients were more likely to default than those already on ART at TB diagnosis; 18% of ARTnaïve patients did not receive ART, and a large proportion (86%) of them had defaulted. Similar findings were reported from public health facilities in Mysore, India, 20 where only 56% of eligible TB patients received ART. It is anticipated that strategies such as 'test and treat' 24 can address this problem to some extent, and therefore have important implications for TB control efforts. The other risk factors for default in the present study, such as being male and having a previous history of TB, are consistent with other studies. [25] [26] [27] [28] [29] In addition to defaulters, 102 patients diagnosed with TB were LTFU, without any information as to whether or not they initiated ATT. There is an urgent need to identify strategies to strengthen links and retention of TB patients detected in the private sector. Use of mHealth technology or facilitating links to RNTCPmonitoring mechanisms through intermediary organisations could be helpful, 17 and should be explored further.
The mortality rate in the study cohort was lower than reported by the RNTCP. This could be attributable to the daily use of ATT for an extended period. However, misclassification of the outcome cannot be ruled out among those who defaulted and were LTFU. In the worst case scenario of sensitivity analysis assuming that all those who defaulted and were LTFU had died, the mortality rate was found to be higher than that of the RNTCP. However, this is an unlikely scenario in view of the findings from other studies, which report that most patients LTFU may have sought care from other health care facilities, public or private.
As seen in other studies, 30 the majority of the deaths occurred within the first 4 months of ATT. Low CD4 count was a risk factor for death. Other studies have established similar associations. 31 It is now known that ART reduces mortality and relapse among TB patients. 12, 32 However, the evidence also suggests 31, 33 that ART is not effective in reducing mortality if the CD4 count remains low despite the use of ART. In the current study, all patients who were already on ART at TB diagnosis and who died during ATT had very low CD4 counts due to poor ART adherence. Stratified analysis among ART-naïve patients diagnosed with TB showed no deaths in the group that could not be started on ART. Contrary to existing evidence, 9 the proportion of deaths was lower among those initiating ART after 8 weeks of TB diagnosis than in those starting earlier. These findings are possibly due to attrition bias 34 and immune reconstitution inflammatory syndrome (IRIS), and therefore need to be interpreted with caution. The new HIV management guidelines are shifting towards higher CD4 cut-offs for ART initiation. 35, 36 This transition is expected to strengthen TB control efforts in PLHIV. However, these benefits may accrue only with sustained ART adherence and retention in care over the long term.
This study was based on a large sample from the private sector. Less is known about daily ATT outcomes among PLHIV in programmatic settings. The study succeeds in bridging this gap to some extent.
The study has several limitations. The findings may not be representative of the entire private sector. Some misclassification in identifying 'treatment failure' is likely. A high default rate increases the likelihood of misclassification and attrition bias, thus favouring the overestimation of survival probability. A sensitivity analysis was performed to address this issue.
In conclusion, the present study indicates that daily ATT can achieve low mortality rates among PLHIV. More evidence would be needed to confirm these findings. A high default rate seen in this study indicates the need to identify newer strategies for the private sector to overcome these challenges. Daily ATT in HIV-TB patients C O N C L U S I O N: Se observó una baja mortalidad global en los pacientes coinfectados por el VIH y la TB que recibían el ATT diario. Es preciso prestar una atención especial a las altas tasas de abandono en los establecimientos del sector privado.
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